<DOC>
	<DOC>NCT00569179</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.</brief_summary>
	<brief_title>A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<criteria>Patients must have histologically documented AML, ALL, MDS, CML, Identification of haploidentical donor LVEF &gt; 45% corrected DLCO &gt; 50% predicted Serum Creatinine &lt;= 2 mg/dL Bilirubin &lt; 2 x ULN AST, ALT &lt; 2 x ULN Age â‰¤ 65 years Performance Status 01 Patients relapsing &lt;6 months after autologous SCT are not eligible. Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection No HIV disease Nonpregnant and nonnursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Myeloid Malignancies</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
	<keyword>CML</keyword>
</DOC>